AIM: To determine whether BAP1 gene and protein expression associates with different prognostic parameters in uveal melanoma and whether BAP1 expression correctly identifies patients as being at risk for metastases, following enucleation of the primary tumour. METHODS: Thirty cases of uveal melanoma obtained by enucleation between 1999 and 2004 were analysed for a variety of prognostic markers, including histological characteristics, chromosome aberrations obtained by fluorescence in situ hybridisation (FISH) and single nucleotide polymorphism (SNP) analysis and gene expression profiling. These parameters were compared with BAP1 gene expression and BAP1 immunostaining. RESULTS: The presence of monosomy of chromosome 3 as identified by the different chromosome 3 tests showed significantly increased HRs (FISH on isolated nuclei cut-off 30%: HR 11.6, p=0.002; SNP analysis: HR 20.3, p=0.004) for death due to metastasis. The gene expression profile class 2, based on the 15-gene expression profile, similarly provided a significantly increased HR for a poor outcome (HR 8.5, p=0.005). Lower BAP1 gene expression and negative BAP1 immunostaining (50% of 28 tumours were immunonegative) were both associated with these markers for prognostication: FISH cut-off 30% monosomy 3 (BAP1 gene expression: p=0.037; BAP1 immunostaining: p=0.001), SNP-monosomy 3 (BAP1 gene expression: p=0.008; BAP1 immunostaining: p=0.002) and class 2 profile (BAP1 gene expression: p<0.001; BAP1 immunostaining: p=0.001) and were themselves associated with an increased risk of death due to metastasis (BAP1 gene expression dichotomised: HR 8.7, p=0.006; BAP1 immunostaining: HR 4.0, p=0.010). CONCLUSIONS: Loss of BAP1 expression associated well with all of the methods currently used for prognostication and was itself predictive of death due to metastasis in uveal melanoma after enucleation, thereby emphasising the importance of further research on the role of BAP1 in uveal melanoma. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIM: To determine whether BAP1 gene and protein expression associates with different prognostic parameters in uveal melanoma and whether BAP1 expression correctly identifies patients as being at risk for metastases, following enucleation of the primary tumour. METHODS: Thirty cases of uveal melanoma obtained by enucleation between 1999 and 2004 were analysed for a variety of prognostic markers, including histological characteristics, chromosome aberrations obtained by fluorescence in situ hybridisation (FISH) and single nucleotide polymorphism (SNP) analysis and gene expression profiling. These parameters were compared with BAP1 gene expression and BAP1 immunostaining. RESULTS: The presence of monosomy of chromosome 3 as identified by the different chromosome 3 tests showed significantly increased HRs (FISH on isolated nuclei cut-off 30%: HR 11.6, p=0.002; SNP analysis: HR 20.3, p=0.004) for death due to metastasis. The gene expression profile class 2, based on the 15-gene expression profile, similarly provided a significantly increased HR for a poor outcome (HR 8.5, p=0.005). Lower BAP1 gene expression and negative BAP1 immunostaining (50% of 28 tumours were immunonegative) were both associated with these markers for prognostication: FISH cut-off 30% monosomy 3 (BAP1 gene expression: p=0.037; BAP1 immunostaining: p=0.001), SNP-monosomy 3 (BAP1 gene expression: p=0.008; BAP1 immunostaining: p=0.002) and class 2 profile (BAP1 gene expression: p<0.001; BAP1 immunostaining: p=0.001) and were themselves associated with an increased risk of death due to metastasis (BAP1 gene expression dichotomised: HR 8.7, p=0.006; BAP1 immunostaining: HR 4.0, p=0.010). CONCLUSIONS: Loss of BAP1 expression associated well with all of the methods currently used for prognostication and was itself predictive of death due to metastasis in uveal melanoma after enucleation, thereby emphasising the importance of further research on the role of BAP1 in uveal melanoma. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Mary Aronow; Yang Sun; Yogen Saunthararajah; Charles Biscotti; Raymond Tubbs; Pierre Triozzi; Arun D Singh Journal: Surv Ophthalmol Date: 2012-06-02 Impact factor: 6.048
Authors: D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher Journal: Oncogene Date: 1998-03-05 Impact factor: 9.867
Authors: Anna E Koopmans; Robert M Verdijk; Rutger W W Brouwer; Thierry P P van den Bosch; Mike M P van den Berg; Jolanda Vaarwater; Christel E M Kockx; Dion Paridaens; Nicole C Naus; Mark Nellist; Wilfred F J van IJcken; Emine Kiliç; Annelies de Klein Journal: Mod Pathol Date: 2014-03-14 Impact factor: 7.842
Authors: Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Kishan Gupta; Colin A McCannel; Mitchell Kamrava; James Lamb; Robert D Almanzor; Tara A McCannel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-02-24 Impact factor: 3.117
Authors: Beryl Royer-Bertrand; Matteo Torsello; Donata Rimoldi; Ikram El Zaoui; Katarina Cisarova; Rosanna Pescini-Gobert; Franck Raynaud; Leonidas Zografos; Ann Schalenbourg; Daniel Speiser; Michael Nicolas; Laureen Vallat; Robert Klein; Serge Leyvraz; Giovanni Ciriello; Nicolò Riggi; Alexandre P Moulin; Carlo Rivolta Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Naoimh Herlihy; Mehmet Dogrusöz; T Huibertus van Essen; J William Harbour; Pieter A van der Velden; Marja C J A van Eggermond; Geert W Haasnoot; Peter J van den Elsen; Martine J Jager Journal: Invest Ophthalmol Vis Sci Date: 2015-01-15 Impact factor: 4.799
Authors: Matthew G Field; Christina L Decatur; Stefan Kurtenbach; Gülçin Gezgin; Pieter A van der Velden; Martine J Jager; Kaleigh N Kozak; J William Harbour Journal: Clin Cancer Res Date: 2016-03-01 Impact factor: 12.531
Authors: Christine D M Roelofsen; Annemijn P A Wierenga; Sjoerd van Duinen; Robert M Verdijk; Jaco Bleeker; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager Journal: Ocul Oncol Pathol Date: 2020-12-15